C

한국파마

032300KOSDAQ의약품 제조업

40.5 / 100

Reference Date: 2026-04-13

Financial Score15.0 / 40
News Sentiment12.5 / 25
Momentum3.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Declined 7.9% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Hanok Pharma focuses on developing and selling prescription drugs for various disease areas such as the central nervous system and circulatory system through its own R&D. It expands its research in biopharmaceuticals and improved drugs via research centers in Daegu and Uijeongbu. Additionally, the company engages in CMO business, producing solid dosage forms and topical solutions, and is expanding its global market through exports and licensing-out deals.

Number of Employees

284people

Average Salary

67.6M KRW

Score Calculation Basis

Detailed Financial Score

PER
Industry Average 14.804.0Point
PBR
1.78Industry Average 1.041.0Point

1.7x industry avg (risky)

ROE
-3.77Industry Average 4.420.0Point

Well below industry avg

Debt Ratio
1.87Industry Average 11.988.0Point

Half of industry avg (excellent)

Trend 2023~20252.0 / 10 points
Revenue Growth Rate
1.0 / 3

Avg ▲2.7% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼58.8% (2-year basis)

ROE Trend
1.0 / 4

Avg ROE 0.6% (declining, 3yr)

Detailed News Sentiment

1 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (8%, downtrend)

Current 11,250Won52-week high 15,99052-week low 10,800
1-month return1.0Point

1m -7.94% (falling)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

4 totalPositive 0Neutral 4Negative 0
  • Neutral주식등의대량보유상황보고서(일반)2026-04-03
  • Neutral정기주주총회결과2026-03-27
  • Neutral사업보고서 (2025.12)2026-03-19
  • Neutral감사보고서제출2026-03-17